MGNX - MacroGenics: Pipeline Looks Very Attractive And Somewhat Overlooked
- MacroGenics is a $1.75bn market cap biotech that's pushing the boundaries of drug development.
- The company has >8 different molecules in development thanks to a platform that generates bispecific, Fc-engineered, dual antibody targeting immuno-oncology assets.
- Margenza has won an approval in HER2+ MBC. Sales will be modest, but a gastric cancer approval could be next.
- Partner Incyte is close to commercialising another asset - Retifanlimab in SCAC - and Flotetuzumab has an accelerated approval shot in AML.
- MacroGenics' well-diversified portfolio stands out as a long-term buy and hold.
For further details see:
MacroGenics: Pipeline Looks Very Attractive And Somewhat Overlooked